Tag Archives: Genentech

Deals Don't Need Science To Be A Success

Deals don’t need science to be a success By Brian McGilligan, Partner, Pharmaceutical Practice, PIPC Ex Pfizer R&D boss, John L. LaMattina recently proclaimed that Big Pharma mergers are crippling science. Whether or not you agree, mergers are a core part of business and the chances of safe-guarding future R&D investment in merged companies will […]
Posted in Global, Guest Blog, Strategy | Also tagged , , , | 2 Comments

Advisory Panel Rejects Avastin For Breast Cancer Treatment

An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time. This is a huge problem for Roche who purchased the treatment as part of its merger […]
Posted in FDA, Safety | Also tagged , , , , , , , | 1 Comment

Avastin Study Shows Promising Data for Cancer Patients

Genentech released the results of its Phase III Avastin study showing that women that take the ovarian cancer treatment in tandem with chemotherapy had a 39 percent improvement in the likelihood of living longer without the disease worsening than patients being treated with just chemotherapy. The data was released at the annual meeting of American […]
Posted in R&D | Also tagged , , , | Leave a comment

Hot Topics at HBA

The 2009 Healthcare Businesswomen’s Association leadership conference is officially underway in sunny California. Last night, festivities got underway with a welcome reception for attendees followed by a “Taste of San Francisco,” which featured lively entertainment and regional cuisine. I had the opportunity to catch up with a few seasoned participants who are widely known throughout […]
Posted in Events | Also tagged , , | 1 Comment

Avastin Gets Green Light for Use in Kidney Cancer

Image by Getty Images via Daylife Score another win for Genentech and its cancer treatment Avastin (bevacizumab). On Monday, the biotech giant, now owned entirely by Roche, announced that FDA has approved the drug for kidney cancer. Avastin blocks new blood vessels from forming and supplying tumors with the nutrients they need to grow and […]
Posted in News | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta